Date: 2012-08-28
Type of information: Licensing agreement
Compound: EB66® cell line for the development of a novel human vaccine platform and candidate vaccine
Company: Vivalis (France) BioFactura (USA)
Therapeutic area:
Type agreement: licensing
Action mechanism:
Disease: undisclosed
Details: Vivalis has signed a non-exclusive research license agreement with BioFactura, Inc. (Rockville, MD) for the development of a novel human vaccine platform and candidate vaccine in the EB66® cell line. Under this agreement, Vivalis will transfer the EB66® cell line and associated know-how to BioFactura to complete the program. Earlier this year, BioFactura was awarded a two-year $1.8 million grant from the Department of Defense (DoD) for studies directed at the development of an improved scalable cell culture bioprocess for the production of virus-like replicon particle (VRP) vaccines. BioFactura’s proposed production methods, which include the EB66® cell line, have the ability to speed up the advanced development process leading to FDA approval for a broad range of VRP vaccines against high-threat pathogens with the potential to offer a significant reduction in costs and production time over current manufacturing processes. This will be the first time the EB66® cell line will have been used in this manner.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
